Bayer is planning to invest USD 2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio. Building on over 7 billion dollars in US pharma research and development (R&D) and manufacturing spend over the past 5 years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market.

Bill Anderson, CEO, Bayer, said, “Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment. The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.”

Bayer is expected to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility’s construction.

Sebastian Guth, Global Chief Operating Officer, Bayer Pharmaceuticals, and President, Bayer, US, said, “The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the US, our fastest-growing pharmaceuticals market, and beyond.”

The flexible, modular campus is designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support our growing portfolio initially in oncology, cardiovascular and renal care.